Please Wait a Moment
X

Articles

01May

CTS Implements HLA Class I and II Testing on the Gemini

01 May, 2019 | Return|

CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini on Monday, April 29th. As previously communicated, the Immucor assay and sample requirements are the same, and the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list are now available on our website.

 

 

 

 

Related

FDA Guidance for Industry for Babesia

On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...

Read More >

Upcoming HCV Testing Algorithm Change

FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...

Read More >

Reminder- Health and Human Services (HHS) email notifications for WNV reactives

Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...

Read More >

Pooled Zika Testing and New CTS Website Functionality- November 29th Update

As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...

Read More >

CTS to Implement the Grifols Procleix Ultrio Elite Assay Beginning June 1, 2020

Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...

Read More >

CTS Dallas and Phoenix Labs Implements WNV Testing on the Panther

CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...

Read More >